Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
679
Views
10
CrossRef citations to date
0
Altmetric
Letter to the Editor

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma

Isabel G. Amslera Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
,
Barbara Jekera Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
,
Behrouz Mansouri Taleghanib Department of Hematology, University Hospital, Bern, Switzerland; View further author information
,
Ulrike Bacherb Department of Hematology, University Hospital, Bern, Switzerland; View further author information
,
Daniel Betticherc Department of Oncology, Kantonsspital, Fribourg, Switzerland; View further author information
,
Thomas Eggerd Department of Oncology, Kantonsspital, Solothurn, Switzerland; View further author information
,
Thilo Zandere Department of Oncology, Kantonsspital, Lucerne, Switzerland; View further author information
,
Jean-Marc Luethif Department of Medical Oncology, Bern University Hospital, Regionalspital, Thun, SwitzerlandView further author information
,
Urban Novaka Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; View further author information
&
Thomas Pabsta Department of Medical Oncology, Bern University Hospital, Bern, Switzerland; Correspondence[email protected]
View further author information
 show all
Pages 511-514 | Received 09 Dec 2017, Accepted 27 Apr 2018, Published online: 08 Jan 2019

References

  • Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003–3015.
  • Sengsayadeth S, Malard F, Savani BN, et al. Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J. 2017;7:e545.
  • McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–3289.
  • McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–1781.
  • Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–1791.
  • Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.
  • Pratt G. Lenalidomide and second malignancies in myeloma patients. Lancet Oncol. 2014;15:253–254.
  • Yang J, Terebelo HR, Zonder JA. Secondary primary malignancies in multiple myeloma: an old nemesis revisited. Adv Hemat. 2012;2012:801495 (9 pages).
  • Musto P, Anderson KC, Attal M, et al. Secondary primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017;28:228-245.
  • Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–342.
  • Gertz MA, Terpos E, Dispenzieri A, et al. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leuk Lymphoma. 2015;56:1723.
  • Schmid A, Friess D, Mansouri Taleghani B, et al. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). Leuk Lymphoma. 2015;56:608–614.
  • Mueller BU, Keller S, Seipel K, et al. Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity. Leuk Lymphoma. 2016;57:1122–1129.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.